Acute Treatment of Migraine Study

Purpose of This Study

 

This is a research study, or clinical trial, to test a new investigational medication. An investigational medication is one that is not approved by the United States Food and Drug Administration (FDA). The purpose of this research study is to determine the effectiveness of intranasal zavegepant compared with placebo in the acute treatment of migraine. About 1750 study participants will be screened and about 1400 study participants will enter into the treatment phase in this study.

Migraine Study Details

 

This study will test zavegepant intranasal investigational medication compared to a placebo for use in the acute treatment of migraine. Placebo is inactive and does not contain any study medication. 

 

If you qualify, your participation in this study will last approximately 11 weeks and will include approximately 3 study visits to the study center.

Why participate?

By joining this study, you will help contribute to our understanding of the treatment of migraine headaches. You will also receive:

 

  • Study-related evaluations of your migraine-related symptoms and overall health.*

  • You may receive compensation for your participation.

*You do not need insurance to participate.

What is a migraine headache?

 

Migraine is a chronic and debilitating disorder that affects approximately 15% of the population. Migraines are characterized by recurrent attacks lasting 4 to 72 hours with multiple symptoms, including pulsating (throbbing) headaches of moderate to severe pain that could be associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia).

 

Biohaven is a clinical stage biopharmaceutical company with innovative drug candidates targeting neurological diseases. Learn more about Biohaven Pharmaceuticals.

  • Facebook Social Icon
  • LinkedIn
  • Twitter Social Icon
  • Instagram
  • YouTube